Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
*Department of Thoracic Oncology, †Cancer Pathology Laboratory, ‡Department of Thoracic Oncology, and §Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.
Fumihiko
F
Hirai
Mitsuhiro
M
Takenoyama
Kenichi
K
Taguchi
Ryo
R
Toyozawa
Eiko
E
Inamasu
Gouji
G
Toyokawa
Tsukihisa
T
Yoshida
Yoshimasa
Y
Shiraishi
Tomoyoshi
T
Takenaka
Masafumi
M
Yamaguchi
Chie
C
Ushijima
Takashi
T
Seto
Sadanori
S
Takeo
Yukito
Y
Ichinose
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
C573239:KIF5B-RET fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors